Literature DB >> 23318566

Measurement of Hba(1C) in patients with chronic renal failure.

Randie R Little1, Curt L Rohlfing, Alethea L Tennill, Steven E Hanson, Shawn Connolly, Trefor Higgins, Charles E Wiedmeyer, Cas W Weykamp, Richard Krause, William Roberts.   

Abstract

BACKGROUND: Carbamylated hemoglobin (carbHb) is reported to interfere with measurement and interpretation of HbA(1c) in diabetic patients with chronic renal failure (CRF). There is also concern that HbA1c may give low results in these patients due to shortened erythrocyte survival.
METHODS: We evaluated the effect of carbHb on HbA(1c) measurements and compared HbA(1c) with glycated albumin (GA) in patients with and without renal disease to test if CRF causes clinically significant bias in HbA(1c) results by using 11 assay methods. Subjects included those with and without renal failure and diabetes. Each subject's estimated glomerular filtration rate (eGFR) was used to determine the presence and degree of the renal disease. A multiple regression model was used to determine if the relationship between HbA(1c) results obtained from each test method and the comparative method was significantly (p<0.05) affected by eGFR. These methods were further evaluated for clinical significance by using the difference between the eGRF quartiles of >7% at 6 or 9% HbA(1c). The relationship between HbA(1c) and glycated albumin (GA) in patients with and without renal failure was also compared.
RESULTS: Some methods showed small but statistically significant effects of eGFR; none of these differences were clinically significant. If GA is assumed to better reflect glycemic control, then HbA(1c) was approximately 1.5% HbA(1c) lower in patients with renal failure.
CONCLUSIONS: Although most methods can measure HbA(1c) accurately in patients with renal failure, healthcare providers must interpret these test results cautiously in these patients due to the propensity for shortened erythrocyte survival in renal failure.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23318566      PMCID: PMC4757846          DOI: 10.1016/j.cca.2012.12.022

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  24 in total

1.  Can glycohemoglobin be used to assess glycemic control in patients with chronic renal failure?

Authors:  Randie R Little; Alethea L Tennill; Curt Rohlfing; Hsiao-Mei Wiedmeyer; Ramesh Khanna; Sharad Goel; Alok Agrawal; Richard Madsen; David E Goldstein
Journal:  Clin Chem       Date:  2002-05       Impact factor: 8.327

2.  Glycemic control and survival in peritoneal dialysis patients with diabetes mellitus.

Authors:  Uyen Duong; Rajnish Mehrotra; Miklos Z Molnar; Nazanin Noori; Csaba P Kovesdy; Allen R Nissenson; Kamyar Kalantar-Zadeh
Journal:  Clin J Am Soc Nephrol       Date:  2011-04-21       Impact factor: 8.237

3.  Carbamylated haemoglobin, urea kinetic modelling and adequacy of dialysis in haemodialysis patients.

Authors:  J T Kwan; E C Carr; A D Neal; J Burdon; M J Raftery; F P Marsh; J L Barron; M R Bending
Journal:  Nephrol Dial Transplant       Date:  1991       Impact factor: 5.992

4.  Glycated haemoglobin and fructosamine in non-diabetic subjects with chronic renal failure.

Authors:  L J Morgan; C B Marenah; A G Morgan; R P Burden; W G John
Journal:  Nephrol Dial Transplant       Date:  1990       Impact factor: 5.992

5.  Glycated albumin and risk of death and hospitalizations in diabetic dialysis patients.

Authors:  Barry I Freedman; Lilian Andries; Zak K Shihabi; Michael V Rocco; Joyce R Byers; Cesar Y Cardona; Michael A Pickard; David L Henderson; Margie V Sadler; Leah M Courchene; Jean R Jordan; Somer S Balderston; Angie D Graham; Vicki L Mauck; Gregory B Russell; Anthony J Bleyer
Journal:  Clin J Am Soc Nephrol       Date:  2011-05-19       Impact factor: 8.237

6.  Comparison of glycated albumin and hemoglobin A1c concentrations in diabetic subjects on peritoneal and hemodialysis.

Authors:  Barry I Freedman; Rajeev N Shenoy; Jonathan A Planer; Kimberly D Clay; Zak K Shihabi; John M Burkart; Cesar Y Cardona; Lilian Andries; Todd P Peacock; Hernan Sabio; Joyce R Byers; Gregory B Russell; Anthony J Bleyer
Journal:  Perit Dial Int       Date:  2010 Jan-Feb       Impact factor: 1.756

7.  Differentiation of acute from chronic renal impairment by detection of carbamylated haemoglobin.

Authors:  A Davenport; S R Jones; S Goel; J P Astley; M Hartog
Journal:  Lancet       Date:  1993-06-26       Impact factor: 79.321

8.  Glycosylated and carbamylated haemoglobin in uraemia.

Authors:  W G Smith; M Holden; M Benton; C B Brown
Journal:  Nephrol Dial Transplant       Date:  1989       Impact factor: 5.992

9.  Estimating average glucose levels from glycated albumin in patients with end-stage renal disease.

Authors:  Jwa-Kyung Kim; Jung Tak Park; Hyung Jung Oh; Dong Eun Yoo; Seung Jun Kim; Seung Hyeok Han; Shin-Wook Kang; Kyu Hun Choi; Tae-Hyun Yoo
Journal:  Yonsei Med J       Date:  2012-05       Impact factor: 2.759

10.  A critical evaluation of glycated protein parameters in advanced nephropathy: a matter of life or death: time to dispense with the hemoglobin A1C in end-stage kidney disease.

Authors:  Barry I Freedman
Journal:  Diabetes Care       Date:  2012-07       Impact factor: 19.112

View more
  15 in total

Review 1.  The National Glycohemoglobin Standardization Program: Over 20 Years of Improving Hemoglobin A1c Measurement.

Authors:  Randie R Little; Curt Rohlfing; David B Sacks
Journal:  Clin Chem       Date:  2018-12-05       Impact factor: 8.327

2.  Physiologic Concepts That May Revise the Interpretation and Implications of HbA1C in Clinical Medicine: An American Perspective.

Authors:  Eric P Smith; Robert M Cohen
Journal:  J Diabetes Sci Technol       Date:  2015-02-17

3.  Analytical evaluation of the ADAMS A1c HA8180T analyzer for the measurement of HbA1c.

Authors:  Eloísa Urrechaga
Journal:  J Clin Lab Anal       Date:  2017-02-25       Impact factor: 2.352

4.  Monitoring Glycemic Control in End-Stage Renal Disease: What Should Be Measured?

Authors:  Elizabeth Selvin; David B Sacks
Journal:  Clin Chem       Date:  2016-12-14       Impact factor: 8.327

5.  Role of Glycated Proteins in the Diagnosis and Management of Diabetes: Research Gaps and Future Directions.

Authors:  Kerry J Welsh; M Sue Kirkman; David B Sacks
Journal:  Diabetes Care       Date:  2016-08       Impact factor: 19.112

6.  Analytical evaluation of the Diazyme glycated serum protein assay on the siemens ADVIA 1800: comparison of results against HbA1c for diagnosis and management of diabetes.

Authors:  Karina Rodriguez-Capote; Kayla Tovell; Deborah Holmes; Janice Dayton; Trefor N Higgins
Journal:  J Diabetes Sci Technol       Date:  2015-01-14

Review 7.  Beyond HbA1c and glucose: the role of nontraditional glycemic markers in diabetes diagnosis, prognosis, and management.

Authors:  Christina M Parrinello; Elizabeth Selvin
Journal:  Curr Diab Rep       Date:  2014       Impact factor: 4.810

8.  Hemoglobin A1c, fasting plasma glucose, and 2-hour plasma glucose distributions in U.S. population subgroups: NHANES 2005-2010.

Authors:  Andy Menke; Keith F Rust; Peter J Savage; Catherine C Cowie
Journal:  Ann Epidemiol       Date:  2013-10-18       Impact factor: 3.797

Review 9.  Interactions between kidney disease and diabetes: dangerous liaisons.

Authors:  Roberto Pecoits-Filho; Hugo Abensur; Carolina C R Betônico; Alisson Diego Machado; Erika B Parente; Márcia Queiroz; João Eduardo Nunes Salles; Silvia Titan; Sergio Vencio
Journal:  Diabetol Metab Syndr       Date:  2016-07-28       Impact factor: 3.320

10.  New-onset diabetes in elderly subjects: association between HbA1c levels, mortality, and coronary revascularization.

Authors:  Orit Twito; Ella Ahron; Anat Jaffe; Shani Afek; Efrat Cohen; Martine Granek-Catarivas; Pinchas Klein; Doron Hermoni
Journal:  Diabetes Care       Date:  2013-07-22       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.